A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)

Condition:   COVID-19 Interventions:   Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector);   Other: Placebo Sponsors:   Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China;   CanSino Biologics Inc.;   Jiangsu Province Centers for Disease Control and Prevention;   Hubei Provincial Center for Disease Control and Prevention Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials